Icaritin plus chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of a plant-based drug (icaritin) and two chemotherapy drugs (AG) for people with advanced pancreatic cancer who have not had treatment before. The goal is to see if the combination works better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced pancreatic cancer that has spread or cannot be removed by surgery.
- You have not received any previous treatment for your cancer (like chemotherapy or targeted therapy).
- You are able to take care of yourself (ECOG performance status 0 or 1).
- Your kidney, liver, and blood counts are within acceptable ranges.
- You do not have other serious medical conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (ATRA, SDK002, chemotherapy, and an immunotherapy) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
This trial studies a new combination of drugs for advanced pancreatic cancer that has spread. The goal is to see if adding the study drug (chiauranib) to standard chemotherapy and immunotherapy can help control the cancer better. It is only for people who have not received prior treatment for their advanced cancer.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
Hear when a new Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.